[go: up one dir, main page]

MX2016013162A - Proceso para la fabricacion de medicamentos. - Google Patents

Proceso para la fabricacion de medicamentos.

Info

Publication number
MX2016013162A
MX2016013162A MX2016013162A MX2016013162A MX2016013162A MX 2016013162 A MX2016013162 A MX 2016013162A MX 2016013162 A MX2016013162 A MX 2016013162A MX 2016013162 A MX2016013162 A MX 2016013162A MX 2016013162 A MX2016013162 A MX 2016013162A
Authority
MX
Mexico
Prior art keywords
manufacture
medicines
viiia
arylsolfonic
compound
Prior art date
Application number
MX2016013162A
Other languages
English (en)
Other versions
MX375638B (es
Inventor
Wei Gu
Tao Zhang
Jing Li
Iding Hans
Jeffrey Stults
LIN Jinguang
Sha Chunbo
Wang Youchu
Zhang Jianqian
Chestakova Alexandra
LINGHU Xin
MEIER Patrik
Zhang Haiming
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2016013162A publication Critical patent/MX2016013162A/es
Publication of MX375638B publication Critical patent/MX375638B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona un proceso para la fabricación de un compuesto de la fórmula (VIIIa) y formas de sales de (VIIIa), donde Rc es un ácido arilsolfónico.
MX2016013162A 2014-04-09 2015-04-08 Proceso para la fabricación de medicamentos. MX375638B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014075011 2014-04-09
PCT/CN2015/076083 WO2015154674A1 (en) 2014-04-09 2015-04-08 Process for the manufacturing of medicaments

Publications (2)

Publication Number Publication Date
MX2016013162A true MX2016013162A (es) 2017-04-27
MX375638B MX375638B (es) 2025-03-06

Family

ID=54287327

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016013162A MX375638B (es) 2014-04-09 2015-04-08 Proceso para la fabricación de medicamentos.
MX2020010384A MX392460B (es) 2014-04-09 2015-04-08 Proceso para la fabricacion de medicamentos

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020010384A MX392460B (es) 2014-04-09 2015-04-08 Proceso para la fabricacion de medicamentos

Country Status (22)

Country Link
US (4) US20170022183A1 (es)
EP (2) EP3494971B1 (es)
JP (3) JP6723926B2 (es)
KR (3) KR20200038553A (es)
CN (3) CN112645927A (es)
AR (1) AR099989A1 (es)
AU (2) AU2015245743B2 (es)
BR (2) BR122020014933B8 (es)
CA (2) CA2945098C (es)
ES (1) ES2733495T3 (es)
HR (1) HRP20191306T1 (es)
IL (2) IL248205B (es)
MX (2) MX375638B (es)
MY (3) MY188526A (es)
NZ (1) NZ725450A (es)
PL (1) PL3129025T3 (es)
RU (1) RU2684102C2 (es)
SG (1) SG11201608421XA (es)
SI (1) SI3129025T1 (es)
TW (2) TWI678366B (es)
WO (1) WO2015154674A1 (es)
ZA (1) ZA201607066B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201800282T1 (it) * 2012-03-01 2018-07-17 Genentech Inc Inibitori delle serina/treonina chinasi
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
UA120506C2 (uk) 2013-12-06 2019-12-26 Дженентек, Інк. Інгібітори серин/треонінкіназ
EP3494971B1 (en) 2014-04-09 2024-07-24 Genentech, Inc. Salts of erk inhibitors
CR20180316A (es) 2015-11-09 2018-10-05 Astrazeneca Ab Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
KR20180134347A (ko) 2016-04-15 2018-12-18 제넨테크, 인크. 암의 진단 및 치료 방법
JP7530829B2 (ja) 2017-09-08 2024-08-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの診断及び治療方法
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
EP3546447A1 (en) * 2018-03-29 2019-10-02 Heidelberg Pharma GmbH Synthesis of (2s,3r,4r)-4,5-dihydroxyisoleucine and derivatives
WO2021110893A1 (en) * 2019-12-05 2021-06-10 Astrazeneca Ab Process and intermediates for the production of formula (i)
CN115710158A (zh) * 2021-08-23 2023-02-24 凯特立斯（深圳）科技有限公司 一种不对称催化制备替格瑞洛中间体的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
US6869966B2 (en) * 2002-09-30 2005-03-22 Banyu Pharmaceutical Co., Ltd. N-substituted-2-oxodihydropyridine derivatives
EP2001849B1 (en) * 2006-03-29 2014-11-26 F. Hoffmann-La Roche AG Pyridine and pyrimidine derivatives as mglur2 antagonists
JP2011503006A (ja) * 2007-11-06 2011-01-27 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌性複素環アミン
SMT201800282T1 (it) * 2012-03-01 2018-07-17 Genentech Inc Inibitori delle serina/treonina chinasi
US9867667B2 (en) * 2014-02-27 2018-01-16 Canon Usa Inc. Placement apparatus
EP3494971B1 (en) 2014-04-09 2024-07-24 Genentech, Inc. Salts of erk inhibitors

Also Published As

Publication number Publication date
JP2020114817A (ja) 2020-07-30
EP3129025A1 (en) 2017-02-15
EP3494971C0 (en) 2024-07-24
JP2021167321A (ja) 2021-10-21
CN106659721B (zh) 2021-01-01
TWI762806B (zh) 2022-05-01
ZA201607066B (en) 2018-05-30
CN106659721A (zh) 2017-05-10
HRP20191306T1 (hr) 2019-10-18
RU2684102C2 (ru) 2019-04-04
EP3494971B1 (en) 2024-07-24
AU2015245743A1 (en) 2016-10-27
CN111777594B (zh) 2023-06-27
BR122020014933B1 (pt) 2022-11-29
CA3167641A1 (en) 2015-10-15
TWI678366B (zh) 2019-12-01
MX2020010384A (es) 2022-05-19
JP6974524B2 (ja) 2021-12-01
BR112016023391A2 (es) 2017-08-15
CN112645927A (zh) 2021-04-13
US20180134685A1 (en) 2018-05-17
ES2733495T3 (es) 2019-11-29
NZ725450A (en) 2022-08-26
BR112016023391B1 (pt) 2022-08-09
JP6723926B2 (ja) 2020-07-15
RU2016139286A3 (es) 2018-10-26
US20200190061A1 (en) 2020-06-18
MX392460B (es) 2025-03-24
US10611753B2 (en) 2020-04-07
IL268690A (en) 2019-10-31
MY188526A (en) 2021-12-18
AU2020220208B2 (en) 2022-03-17
EP3129025A4 (en) 2018-01-17
JP2017510620A (ja) 2017-04-13
RU2016139286A (ru) 2018-05-15
KR20230006043A (ko) 2023-01-10
US11098028B2 (en) 2021-08-24
KR102490955B1 (ko) 2023-01-19
BR122020014933B8 (pt) 2022-12-13
BR112016023391A8 (pt) 2018-04-17
MY196320A (en) 2023-03-24
US11066389B2 (en) 2021-07-20
EP3494971A1 (en) 2019-06-12
US20170022183A1 (en) 2017-01-26
CA2945098A1 (en) 2015-10-15
IL248205B (en) 2019-09-26
AU2015245743B2 (en) 2020-09-24
EP3129025B1 (en) 2019-05-15
CA2945098C (en) 2022-10-04
WO2015154674A1 (en) 2015-10-15
MX375638B (es) 2025-03-06
AR099989A1 (es) 2016-08-31
PL3129025T3 (pl) 2019-11-29
TW201945358A (zh) 2019-12-01
KR20200038553A (ko) 2020-04-13
SG11201608421XA (en) 2016-11-29
CN111777594A (zh) 2020-10-16
TW201620897A (zh) 2016-06-16
IL248205A0 (en) 2016-11-30
US20190367484A1 (en) 2019-12-05
AU2020220208A1 (en) 2020-09-10
KR20160133566A (ko) 2016-11-22
MY198371A (en) 2023-08-28
SI3129025T1 (sl) 2019-08-30

Similar Documents

Publication Publication Date Title
MX2016013162A (es) Proceso para la fabricacion de medicamentos.
CL2018001790A1 (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este (divisional solicitud 201602748)
HUE057926T2 (hu) Eljárás tiokarbonátok elõállítására
PE20171094A1 (es) Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
MX2017002214A (es) Proceso para la preparacion de 5-fluoro-1h-pirazoles partiendo de hexafluoropropeno.
HUE059670T2 (hu) Eljárás új nitrogén-tartalmú vegyület vagy sója és intermedierjei elõállítására
MX2021012440A (es) Farmacos precursores de oxabicicloheptanos.
CL2020000217A1 (es) Inhibidores de ror gamma.
TW201613871A (en) Process for the preparation of 5-fluoro-1H-pyrazoles starting from hexafluoropropene
CL2020000190A1 (es) Inhibidores de ror-gamma.
HUE060836T2 (hu) A savas rész társkristályait tartalmazó pezsgõkészítmények
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
MX389099B (es) Proceso para la preparación de 3-cloro-2-vinilfenilsulfonatos.
BR112017019176A2 (pt) processos para a preparação de fluorocetolídeos
BR112017023877A2 (pt) método de produção de um composto à base de mercúrio, o composto à base de mercúrio, os métodos para utilização do composto à base de mercúrio e as utilizações do composto à base de mercúrio
MX382659B (es) Proceso para la preparación de derivados de tiazol.
BR112018069255A2 (pt) processos para a preparação de ácidos heteroaril carboxílicos
MX2016015623A (es) Proceso para la preparacion de derivados dihidroisoxazol.
BR112017000697A2 (pt) “processo para a produção de compostos de biaril”
MX2016016398A (es) Preparacion de piperidin-4-carbotioamida.
CR20150484A (es) Método de producción de compuestos de piridazinona
CL2017001466A1 (es) Un proceso para la fabricación de idalopirdina
BR112018007282A2 (pt) métodos para síntese total de resolvina e1
BR112018012696A2 (pt) processo aperfeiçoado para fabricação de crotonilaminopiridinas

Legal Events

Date Code Title Description
FG Grant or registration